Gefitinib is more effective in never-smokers with non-small-cell lung cancer
Author Information
Author(s): Lim S-T, Wong E-H, Chuah K-L, Leong S-S, Lim W-T, Tay M-H, Toh C-K, Tan E-H
Primary Institution: National Cancer Centre, Singapore
Hypothesis
Is never-smoking status a predictor of response to gefitinib in patients with advanced non-small-cell lung cancer?
Conclusion
Never-smoking status is an important clinical predictor of a favourable response to gefitinib.
Supporting Evidence
- Never-smokers had a 6.1 higher odds of response compared to smokers.
- Responders had a longer median overall survival compared to nonresponders (17.5 vs 7 months).
- Patients with good ECOG status had a 0.42 times lower risk of death compared to those with poor status.
Takeaway
This study found that patients with lung cancer who have never smoked respond better to a drug called gefitinib compared to those who have smoked.
Methodology
The study retrospectively analyzed 110 patients with advanced non-small-cell lung cancer treated with gefitinib, assessing response and survival outcomes using logistic and Cox regression analyses.
Potential Biases
Potential bias due to the retrospective nature of the study and the specific patient population.
Limitations
The study is retrospective and may not account for all confounding factors.
Participant Demographics
The median age was 55.8 years, with 60% being never-smokers and 93% of Chinese origin.
Statistical Information
P-Value
0.005
Confidence Interval
95% CI=1.7, 21.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website